Oncological outcomes in low-,intermediate- and high D'Amico-risk patients undergoing laparoscopic radical prostatectomy at a single UK centre

Abstract

Background and purpose

Laparoscopic radical prostatectomy (LRP) is an established treatment option for patients with prostate cancer in selected centres with appropriate expertise. The goal of LRP is to achieve excellent cancer control whilst attempting to preserve normal urinary continence and erectile function. We studied our single-centre experience evaluating the oncological outcomes in patients undergoing LRP.

Patients and methods

Three hundred and six patients underwent LRP between 2005 and 2011. Patients were divided into D'Amico low-, intermediate- and high-risk groups.

Results

The mean age was 61.9 years (range 46-74 years). The two most important factors predictive of positive surgical margins (PSMs) at LRP were the initial prostate-specific antigen (PSA) level and tumour stage at diagnosis. The overall PSM rate was 26.7%. For low D'Amico-risk patients, the PSM was 24.5%, intermediate-risk patients had a PSM of 32.4%, while high-risk patients had a PSM of 13.6%; 6.4% (nine of 139) of patients sampled had evidence of lymph node-positive disease. Five-year PSA progression-free survival rates were 83% in low-risk patients, 57% in intermediate-risk and 41% in high-risk patients.

Conclusion

LRP offers good oncological outcomes in the low- and intermediate-risk groups with low incidence of biochemical recurrence for patients with localised disease. Our high-risk group has a low incidence of PSM and a five-year PSA progression-free survival rate of 41%. Patients with high-risk, but non-metastatic, prostate cancer can be offered a minimally invasive prostatectomy in an experienced centre.

Keywords

Laparoscopy prostatectomy oncological outcome D'Amico classification biochemical recurrence (BCR)laparoscopic radical prostatectomy (LRP)prostate-specific antigen (PSA)radical prostatectomy (RP)

Get full access to this article

View all access options for this article.

References

Office for National Statistics. Cancer statistics registrations. Registrations of cancer diagnosed in 2009. http://www.ons.gov.uk/.

Mokete

, Shackley

, Betts

CD.

The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.

BJU Int 2006; 97; 266–269.

Crawford

ED.

Understanding the epidemiology, natural history and key pathways involved in prostate cancer -

Urology. 2009 May;73(5 Suppl): S4–10

Vasdev

, Kass-Iliyya

, Patel

Developing a laparoscopic radical prostatectomy service: Defining the learning curve.

J Endourol 2012; 26: 903–910.

Han

, Partin

, Pound

CR.

Long term biochemical disease-free and cancer-specific survival following anatomic retropubic radical prostatectomy. The 15-year John Hopkins experience.

Urol Clin North Am 2001; 28: 555–565.

Guillanneau

, and Vallancien

. Laparoscopic radical prostatectomy: The Montsouris technique. J Urol 2000; 163: 1643–1649.

Pound

, Partin

, Epstein

JI.

Prostate-specific antigen after anatomic retropubic radical prostatectomy. Patterns of recurrence and cancer control.

Urol Clin North Am 1997; 24: 395–406.

Hussain

, Gunnell

, Donovan

Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004.

BJU Int 2008; 101: 547–555.

Hanchanale

, McCabe

, and Javle . Radical prostatectomy practice in England. Urol J 2010; 7: 243–248.

10.

Bianco

Jr , Scardino

, and Eastham

JA.

Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function (“trifecta”).

Urology 2005; 66 (5 Suppl): 83–94.

11.

Chun

, Graefen

, Zacharias

Anatomic radical retropubic prostatectomy-long-term recurrence free survival rates for localized prostate cancer.

World J Urol 2006; 24: 273–280.

12.

Hull

, Rabbani

, Abbas

Cancer control with radical prostatectomy alone in 1,000 consecutive patients.

J Urol 2002; 167 (2 Pt 1): 528–534.

13.

Walz

, Joniau

, Chun

FK.

Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy.

BJU Int 2011; 107: 765–770.

14.

D'Amico

, Whittington

, Malkowicz

SB.

Biochemical outcome after radical prostatectomy, external beam radiotherapy or interstitial radiation therapy for clinically localized prostate cancer.

JAMA 1998; 280: 969–974.

15.

D'Amico

, Cote

, Loffredo

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer.

J Clin Oncol 2002; 20: 4567–4573.

16.

Busch

, Stephan

, Herold

Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: A single-centre experience.

BJU Int 2012; 110 (11 Pt C): E985–E990.

17.

Touijer

, Secin

, Cronin

AM.

Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience.

Eur Urol 2009; 55: 1014–1019.

18.

Spahn

, Joniau

, Gontero

Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: A European multi-institutional study of 712 patients.

Eur Urol 2010; 58: 1–7, discussion 10-11.

19.

Ploussard

, Salomon

, Allory

Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer.

BJU Int 2010; 106: 86–90.

20.

Cronin

, Godoy

, and Vickers

AJ.

Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates.

J Urol 2010; 183: 984–989.

21.

Berglund

, Jones

, Ulchaker

JC.

Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: A prospective analysis.

Urology 2006; 67: 1253–1256.

22.

Kupelian

, Katcher

, Levin

External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.

Cancer J Sci Am 1997; 3: 78–87.

23.

Wyler

, Sulser

, Seifert

HH.

Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer.

Urology 2006; 68: 883–887.

24.

Boorjian

, Thompson

, Siddiqui

Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.

J Urol 2007; 178 (3 Pt 1): 864–870, discussion 870-871.

25.

Joslyn

, and Konety

BR.

Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer.

Urology 2006; 68: 121–125.

26.

Miyake

, Hara

, Kurahashi

Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR.

Clin Cancer Res 2007; 13: 1192–1197.

27.

Serni

, Masieri

, Minervini

Cancer progression after anterograde radical prostatectomy for pathologic Gleason score 8 to 10 and influence of concomitant variables.

Urology 2006; 67: 373–378.

28.

Messing

, Manola

, Yao

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.

Lancet Oncol 2006; 7: 472–479.

29.

Bader

, Burkhard

, Markwalder

Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?

J Urol 2003; 169: 849–854.

30.

Thompson

Jr , Tangen

, Paradelo

Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial.

JAMA 2006; 296: 2329–2335.

31.

Bolla

, van Poppel

, Collette

Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911).

Lancet 2005; 366: 572–578.

32.

Messing

, Manola

, Sarosdy

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

N Engl J Med 1999; 341: 1781–1788.

33.

Huggins

, Stevens

Jr , and Hodges

CV.

The effect of castration on advanced carcinoma of the prostate gland.

Arch Surg 1941; 43: 209.

34.

Dorff

, Flaig

, Tangen

CM.

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.

J Clin Oncol 2011; 29: 2040–2045.

35.

Byar

DP.

Treatment of prostatic cancer: Studies by the Veterans Administration cooperative urological research group.

Bull N Y Acad Med 1972; 48: 751–766.

36.

RADICALS (Radiotherapy and androgen deprivation in combination after local surgery) - A randomised controlled trial in prostate cancer, http://www.radicals-trial.org/ (2013, accessed 17 September 2012).